Dr. Timothy Scholl
Dr. Timothy Scholl
Dr. Timothy Scholl
Mid-Career Investigator

Darlene Goodine
Administrative Assistant

Mid-Career Investigator

Molecular imaging is an emerging imaging specialty that develops novel technologies to non-invasively assess molecular and cellular processes in living entities. As cancer treatments become more individualized, molecular imaging is becoming an increasingly valuable tool to characterize tumours and their response to a specific therapy.

A research group led by Dr. Timothy Scholl at the Imaging Research Laboratories of the Robarts Research Institute (Western University) is focusing on developing new agents and imaging methods to image cellular metabolism, tissue pH and the concentration of endogenous sodium in tissue.

Dr. Scholl recently led a novel prostate imaging study to non-invasively assess tumour aggressiveness. Using a novel detection system that he developed for measurement of sodium with MRI in the prostate, he imaged men with biopsy-proven prostate cancer prior to surgery. He compared tissue sodium concentration measured in prostate tumours with pathological assessment after prostatectomy. The results showed a very strong correspondence between sodium concentration in tumours and their aggressiveness. This suggests that sodium MRI combined with standard MRI protocols could potentially discriminate between indolent and aggressive disease. With further research, it may be possible that this combined imaging could ultimately replace serial biopsies for active surveillance of men with low- and intermediate-risk prostate cancer.

Tumour metabolism changes rapidly in response to therapy compared with morphological or functional changes. Prompt characterization of metabolism can provide timely therapeutic assessment to determine if a treatment has elicited the desired effect or whether another therapy should be considered. Magnetic resonance spectroscopic imaging (MRSI) of in vivo metabolism of 13C-enriched contrast agents is an emerging method for molecular imaging of disease. One of Dr. Scholl’s research interests is the use of hyperpolarized 13C-enriched compounds to measure metabolic changes within tumours as they respond to therapy. In a preclinical 13C imaging study, he demonstrated that measurement of tumor metabolism with hyperpolarized [1-13C]pyruvate MRSI can detect very early changes in lactate dehydrogenase activity in response to therapy. These changes, which were apparent as early as within two days of initiation of treatment, were correlated with subsequent measurements of tumor response or progression assessed by tumor volume measurements. Early assessment of therapeutic response is highly desirable in aggressive cancers to prompt alternative or salvage therapies or to improve end-of-life care.

Experience & Education
  • Research Associate, Medical Physics, Department of Physics and Astronomy, Western University
  • Postdoctoral Fellow, Atomic and Molecular Physics, Western University
  • PhD Physics, Department of Physics and Astronomy, Western University
Current Affiliations
  • Mid-Career Investigator, OICR
  • Scientist, Imaging Research Laboratories, Robarts Research Institute, Western University
  • Assistant Professor, Medical Biophysics, Department of Medical Biophysics, Western University
  • Assistant Professor, Medical Physics (Cross Appointment), Department of Physics and Astronomy, Western University
Select Publications

See Dr. Scholl’s recent publications on PubMed.

Research Areas
Early Detection and Diagnosis
Disease Areas
Opportunities to Collaborate

Dr. Scholl welcomes collaboration. Contact him directly for more information.

For more opportunities to collaborate with OICR researchers, visit OICR’s Collaborative Research Resources directory.